Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Docetaxel (Primary) ; Nimotuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 26 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Sep 2009 New trial record